Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.56 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118591 | 0.86 | NFE2L2 (0.79) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL3301377 | 0.86 | NFE2L2 (0.72) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL1546324 | 0.84 | NFE2L2 (0.59) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL2099078 | 0.84 | CYP1A2 (0.77) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 | |
| O-Veratraldehyde SCHEMBL28289918 | 0.83 | SRC (0.67) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL4642599 | 0.83 | NFE2L2 (0.58) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| O-Veratraldehyde SCHEMBL29923149 | 0.83 | SRC (0.67) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL57085 | 0.83 | NFE2L2 (0.58) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL26603685 | 0.83 | NFE2L2 (0.58) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 | |
| SCHEMBL6632658 | 0.83 | NFE2L2 (0.61) | NFE2L2CYP1A1CYP1A2CYP1B1PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492384-B2 | Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-07-23 | — | — | US | claimed |
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-12-31 | — | — | US | claimed |
| EP-0538194-B1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA GEIGY AG (CH) | 1997-06-04 | — | — | EP | claimed |
| WO-1996006102-A1 | PROCESS FOR THE PREPARATION OF OLIGOSACCHARIDE MIXTURES | CIBA-GEIGY AG (CH) | 1996-02-29 | — | — | WO | claimed |
| US-5393878-A | Pyrimidine nucleosides having cyclopentafuran skeleton | CIBA-GEIGY CORPORATION (US) | 1995-02-28 | — | — | US | claimed |
| US-5332814-A | Process for the preparation of carbacyclic nucleosides, and intermediates | CIBA-GEIGY CORPORATION (US) | 1994-07-26 | — | — | US | claimed |
| US-5319080-A | Antiviral agents | CIBA-GEIGY CORPORATION (US) | 1994-06-07 | — | — | US | claimed |
| EP-0542681-A1 | Process for the preparation of carbocyclic nucleosides and its intermediates | CIBA-GEIGY AG (CH) | 1993-05-19 | — | — | EP | claimed |
| EP-0538194-A1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | claimed |
| CN-110366556-B | Antibacterial peptide macrocyclic compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-110494442-B | Peptide macrocycles and their use in the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-114008065-A | Glycyrrhetinic acid derivatives for treating hyperkalemia | 阿德利克斯股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3921327-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163642-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| EP-0577558-A2 | Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates | CIBA-GEIGY AG (CH) | 1994-01-05 | — | — | EP | disclosed |
| US-5268464-A | Process for the preparation of nucleosides | CIBA-GEIGY CORPORATION (US) | 1993-12-07 | — | — | US | disclosed |
| EP-0563010-A2 | Method of preparation of nucleosides | CIBA-GEIGY AG (CH) | 1993-09-29 | — | — | EP | disclosed |
| EP-0542681-A1 | Process for the preparation of carbocyclic nucleosides and its intermediates | CIBA-GEIGY AG (CH) | 1993-05-19 | — | — | EP | disclosed |
| EP-0538194-A1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | disclosed |
| US-4118561-A | ANTIBACTERIAL, SYNERGISTIC, ANTI-CANCER ACTIVITY, ANTI-FOLIC ACID ACTIVITY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | CACNA1B, CACNA1C, ORAI1 | NFE2L2 3063/4885CYP1A1 3819/4885CYP1A2 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.